1. Home
  2. Labeler Index
  3. Remedyrepack Inc.
  4. 70518-3804
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Levetiracetam NDC 70518-3804 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Remedy_Label - Remedy Label

Remedy_Label - Remedy Label

This is a description of a medication called levETIRAcetam, available in the form of an oral solution. Each cup contains 10 mL of the solution with a strength of 1000mg. The medication is repackaged by RemedyRepack Inc. The lot number and expiration date are not available. The manufacturer is Aurohindo located in Nagar, India. The National Drug Code (NDC) for this product is 70518-3804-00, and the source NDC is 65862-0250-47. The medication should be stored between 20-25°C (68-77°F) with excursions permitted between 15-30°C (59-86°F) according to the United States Pharmacopeia (USP) guidelines. The text also advises keeping this medication, as well as all medications, out of the reach of children. For detailed usage instructions, refer to the package insert.*

MM2 - levETIRAcetam 1000mg 10mL 70518 3804 01

MM2 - levETIRAcetam 1000mg 10mL 70518 3804 01

Not available*

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 1: Responder Rate (≥50% Reduction from Baseline) in Study 1 - levetiracetam fig1

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 2: Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A - levetiracetam fig2

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 3: Responder Rate (≥50% Reduction from Baseline) in Study 3 - levetiracetam fig3

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 4: Responder Rate (≥ 50% Reduction from Baseline) in Study 4 - levetiracetam fig4

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Table 15: Median Percent Reduction from Baseline in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

This text provides a graph depicting the responder rate (250% reduction from baseline) in PGTC seizure frequency per week in Study 7. The graph shows the percentage of patients on placebo (N<4) and levetiracetam (N:79) who achieved a reduction in seizure frequency. It indicates a statistically significant difference between the two groups. The graph also includes percentages at various intervals, such as 100%, 90%, 80%, 72.2%, 60%, 50%, 45.2%, 30%, 20%, and 10%.*

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.